NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD)
Clinical trials for NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) explained in plain language.
Never miss a new study
Get alerted when new NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) trials appear
Sign up with your email to follow new studies for NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New eye injection for wet AMD passes early safety check
Disease control OngoingThis early-stage trial tests the safety of an experimental drug called OCU-10-C-110, given as an eye injection, in 24 people with wet age-related macular degeneration (nAMD). The study aims to find safe doses and check for side effects. Participants must have active disease and h…
Matched conditions: NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD)
Phase: PHASE1 • Sponsor: Ocugenix Corporation • Aim: Disease control
Last updated May 17, 2026 08:52 UTC
-
Gene therapy for wet AMD: is it safe Long-Term?
Disease control OngoingThis study follows 12 people who already received a gene therapy called EXG102-031 for wet age-related macular degeneration (a leading cause of vision loss). The main goal is to see if the treatment is safe over 4 years by tracking any side effects. Researchers will also check if…
Matched conditions: NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD)
Phase: PHASE1 • Sponsor: Exegenesis Bio • Aim: Disease control
Last updated May 17, 2026 08:50 UTC
-
Gene therapy shot could end monthly eye injections for wet AMD
Disease control OngoingThis study tests a one-time gene therapy called RGX-314 for people with wet age-related macular degeneration (nAMD), a leading cause of vision loss. Currently, patients need frequent eye injections to control the disease. The trial aims to see if RGX-314 can provide similar or be…
Matched conditions: NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD)
Phase: PHASE2 • Sponsor: AbbVie • Aim: Disease control
Last updated May 15, 2026 11:54 UTC
-
New eye drops could offer Needle-Free hope for wet AMD patients
Disease control OngoingThis study tests whether KHK4951 eye drops can safely improve vision in people with wet age-related macular degeneration (nAMD), a leading cause of vision loss. About 180 participants will use the eye drops or a placebo for several months. The goal is to see if the drops can redu…
Matched conditions: NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD)
Phase: PHASE2 • Sponsor: Kyowa Kirin Co., Ltd. • Aim: Disease control
Last updated May 13, 2026 16:03 UTC
-
New eye implant could cut treatment visits for blinding disease
Disease control OngoingThis study tests whether a refillable eye implant (Port Delivery System) filled with the drug ranibizumab can be safely refilled every 36 weeks instead of every 24 weeks for people with wet age-related macular degeneration. About 451 participants who have already responded to sta…
Matched conditions: NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD)
Phase: PHASE3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated May 13, 2026 15:59 UTC
-
Breakthrough eye drug could slash wet AMD shots to twice a year
Disease control OngoingThis study tests a medicine called faricimab, given as an eye injection, for people with wet age-related macular degeneration (AMD) who have not been treated before. The goal is to see if injections every 24 weeks (about twice a year) can safely maintain or improve vision. About …
Matched conditions: NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD)
Phase: PHASE4 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated May 04, 2026 16:25 UTC
-
Japanese health data study reveals Real-World use of eye drug
Knowledge-focused OngoingThis study reviews existing health records from about 3000 people in Japan who received aflibercept 8 mg injections for two eye conditions that cause vision loss. Researchers will describe the patients' characteristics and how the drug was used over one year. No new treatments or…
Matched conditions: NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD)
Sponsor: Bayer • Aim: Knowledge-focused
Last updated May 17, 2026 09:01 UTC
-
New eye Drug's Real-World impact under the microscope
Knowledge-focused OngoingThis study looks at how well the eye injection aflibercept 8 mg works for people with vision loss from age-related macular degeneration (nAMD) or diabetic macular edema (DME). Researchers will collect data from 2500 adults already prescribed the drug by their doctors, tracking vi…
Matched conditions: NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD)
Sponsor: Bayer • Aim: Knowledge-focused
Last updated May 01, 2026 15:58 UTC